KUALA
LUMPUR: A Malaysian prince is promoting
a novel weapon against the worsening scourge of dengue fever: a protein
"pill" that starves mosquito larvae and could revolutionise the
global dengue fight.
It is a
fight that is intensifying: more than 2.5 billion people -- around 40 percent
of Earth's population -- live in areas susceptible to the mosquito-borne virus,
with up to 100 million infected annually, according to the World Health
Organisation.
Dengue
kills 20,000 people worldwide every year, and its complexity -- and what health
advocates say is a lack of priority given to the race to find cures for higher
profile viruses such as AIDS -- means a vaccine has proved elusive.
It is
mainly transmitted to humans by the aedes aegypti mosquito, and causes symptoms
including high fever, body aches, rashes and heavy fatigue. In severe cases,
white blood cells drop to potentially fatal levels.
Enter
Prince Naquiyuddin Jaafar, one of the most popular members of Malaysia's
nobility, whose anti-dengue technology targets the offspring of mosquitoes in a
bid to win the battle against the virus-spreading pest.
A
former diplomat and son of Malaysia's past king, Naquiyuddin, 65, he has been
involved in a wide range of philanthropic and charitable pursuits, but dengue
has been a particular passion.
It is a
growing problem in Malaysia, where cases surged 22 percent to 6,141 from
January to March this year, with 17 deaths. Just eight dengue deaths were
reported for all of 2011.
Among
Naquiyuddin's diverse business activities is the biotech company he founded in
2007, EntoGenex, which has taken a pre-existing protein called the Trypsin
Modulating Oostatic Factor, or TMOF, and developed it into what he calls a
fatal "diet pill" for mosquitoes.
TMOF is
mixed into yeast cells which are then inserted in rice husks, allowing them to
float on water where they will be eaten by mosquito larvae, said Alan Brandt,
EntoGenex's research head. "Larvae love yeast," he added.
Once
consumed, it shuts down the mosquito larvae's digestive systems, starving them
to death before they can grow and spread dengue, Naquiyuddin said as he showed
slides and photographs of dead mosquitos at the firm's high-tech research
facility in downtown Kuala Lumpur.
"The
'pill' has a 100 percent success rate against all larvae species within 24
hours, and there is no way for resistance to build as it is not a toxic
chemical but a protein which only affects mosquitos," Naquiyuddin said.
The
protein stops production of trypsin, a critical enzyme without which digestion
cannot occur.
TMOF is
harmless to animals and humans, Brandt said, washing a handful of the rice
husks down with a glass of water in his laboratory as proof.
The
firm has combined the TMOF with the equally tongue-twisting bacillus
thuringiensis israelensis (Bti) bacteria, which eats holes in the guts of
larvae but is non-toxic to people.
Most
larvae die within an hour, and nearly all within 24 hours, according to
EntoGenex, which has held several successful Malaysian field trials with
universities and health authorities.
"What
they have come up with is quite remarkable in combining Bti and TMOF, and the
field trials have shown that there is success in using it," said the
Malaysian Health Ministry's Disease Control Division director Chong Chee
Kheong.
Although
known for hundreds of years, dengue has emerged as a global health problem in
recent decades as cases have rapidly mounted.
This
spread has been blamed on factors including population growth, urbanisation,
and increased human mobility taking the disease to new areas.
Authorities
in Malaysia are unsure of the reasons driving the recent spike in cases there,
but have speculated that wetter weather as a result of changing climate
patterns could be a factor.
Current
methods of mosquito control include fogging with chemicals such as the
insecticide DDT which can be harmful to both humans and animals, and to which
insects can develop a resistance.
Malaysia
in 2010 released 6,000 genetically modified mosquitoes designed to have
offspring with shorter lifespans but no more releases were made amid concerns
as to how the insects would interact with their cousins in the wild.
Naquiyuddin's
"pill" is now registered for use in Malaysia, Pakistan and the
Philippines, while Ghana, South Africa, Cameroon and Sri Lanka are either
conducting field trials or seeking approvals to use it.
He
hopes it could potentially become a weapon in the even larger fight against
malaria, which kills an estimated 650,000 people per year.
More
than $5 billion is needed annually to control malaria but only $1.8 billion is
being put into the fight, according to Roll Back Malaria, a group that carries
out global anti-malaria campaigns.
The
"pill", which costs about one-eighth the price of manufacturing
conventional neurotoxins like DDT, will lower costs dramatically, said
Naquiyuddin.
"We
are offering a cheaper and much healthier alternative to fighting dengue and
malaria, and this is why we are in the business: to improve the quality of life
of people, while helping to solve a major health threat," he said.
"If
it means my wife and family will never again have to worry about dengue, then I
urge the government and businesses to help make it available to everyone,"
said Ahmad Ismail, 47.
A
recent field trial in the suburb where he lives north of the capital Kuala
Lumpur caused dengue cases to disappear, said Ahmad, an engineer whose wife was
struck down with the virus just months before the trial. She later recovered.
-
AFP/al
No comments:
Post a Comment